Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

NCT00189306

Superficial Basal Cell Carcinoma

COMPLETED PHASE3

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

NCT00314756

Basal Cell Carcinoma

COMPLETED PHASE4

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

NCT00189241

Basal Cell Carcinoma

COMPLETED PHASE3

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

NCT00129519

Basal Cell Carcinoma

COMPLETED PHASE3

Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery

NCT01212562

Basal Cell Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Basal Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nodular BCC of the eyelid

Patients with nodular BCC of the eyelid

Group Type EXPERIMENTAL

Imiquimod 5% cream

Intervention Type DRUG

Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imiquimod 5% cream

Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

immunomodulator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma).
* Patients with clinical counter indication for reconstructive surgery (high surgical risk).
* Patients who have refused a restorative surgery. (aesthetic reasons)
* Patients who have signed the free and informed consent.

Exclusion Criteria

* Patients who have a hypersensitivity reaction to the formula components.
* Children under 12 years of age.
* Pregnant and breastfeeding women.
* Patients whose injury was not confirmed by anatomical and pathological study.
* Individuals with previous autoimmune or inflammatory disease.
* Patients who have refused to sign the free and informed term of consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No